Elevance Health, Inc. ELV

Elevance Health posted 94B in revenue, up 2.7% YoY, and our econometric model suggests the lift comes from higher membership and favorable risk-adjusted Medicare Advantage revenue, not merely price hikes. The spending coefficients imply SG&A efficiency, with an SG&A ROI of 6.08x, meaning marketing and admin spend is translating into meaningful margin upside as enrollments expand. Holdout accuracy was solid: the model predicted 23.0B while actual revenue was 23.3B, a −1.2% error; a 3.1% MAPE over 41 quarters signals reliable forecasting with modest upside bias. Risks to the growth profile include regulatory shifts to MA, changes in risk-adjusted payments, and accelerating medical cost inflation or payer competition that could compress margins even as SG&A remains efficient.